Emerging therapies against infections with Pseudomonas aeruginosa

DOI Web Site Web Site Web Site 1 Citations

Description

<ns4:p>Infections with <ns4:italic>Pseudomonas aeruginosa </ns4:italic>have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. <ns4:italic>P. aeruginosa </ns4:italic>is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.</ns4:p>

Journal

  • F1000Research

    F1000Research 8 1371-, 2019-08-07

    F1000 Research Ltd

Citations (1)*help

See more

Report a problem

Back to top